Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Homo sapiens

ABSTRACT: A Randomized Controlled Trial of Oral Probiotics in Orthodontic Patients

PROVIDER: PRJNA451372 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR7080760_1.fastq.gz	Fastqsanger.gz
	SRR7080760_2.fastq.gz	Fastqsanger.gz
	SRR7080770_1.fastq.gz	Fastqsanger.gz
	SRR7080770_2.fastq.gz	Fastqsanger.gz
	SRR7080780_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 260

Similar Datasets

Probiotics in alleviating asthmatic symptoms

Project description:Asthma is multi-factorial disorder, and microbial dysbiosis enhances lung inflammation and asthma-related symptoms. Probiotics has shown anti-inflammatory effect and could regulate the gut-lung axis. Thus, a three-month randomized, double-blind, and placebo-controlled human trial was performed to investigate the adjunctive efficacy of probiotics in managing asthma.

2021-08-29 | MSV000088033 | MassIVE

Project description:Randomized placebo controlled trial of oral tannin supplementation in COVID-19 patients

| PRJNA856489 | ENA

JAK3/TEC and TYK2/JAK1 inhibitors demonstrate significant improvement in scalp alopecia areata biomarkers

Project description:We present the biopsy sub-study results from the first randomized, placebo-controlled clinical trial in patients with alopecia areata (AA) with ≥50% scalp hair loss and ≤7 years since the last AA episode. In this sub-study, we evaluated the molecular responses to PF-06651600, an oral inhibitor of JAK3 and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family, and PF-06700841, an oral TYK2/JAK1 inhibitor, versus placebo in nonlesional and lesional scalp biopsies of biopsy samples from patients with AA.

2022-01-25 | GSE148346 | GEO

BMS_IM101042_Baseline_WB_study

Project description:The goal of this study is to define the molecular signatures of SLE patients at baseline in BMS IM101042 trial. IM101042 (NCT00119678) is a phase IIb, multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of abatacept vs placebo on a background of oral glucocorticosteroids in the treatment of subjects with systemic lupus erythematosus and the prevention of subsequent lupus flares, sponsored by Bristol-Myers Squibb.

2018-02-07 | GSE110174 | GEO

CLARITY study: Expression data from RRMS patients treated with Oral Cladribine versus Placebo at week 96

Project description:The CLARITY trial (NCT00213135) was designed as a double-blind, placebo-controlled study to allow the best comparison of absolute efficacy and safety of oral cladribine in RRMS subjects. 1326 patients with relapsing MS were randomized (1:1:1) to receive cladribine tablets 3.5 mg/kg or 5.25 mg/kg bodyweight or placebo. Gene expression data in whole blood samples at 96 weeks were prepared according to standard Affymetrix protocols Gene expression data in whole blood samples at 96 weeks were available from patients randomized to placebo (n=57), cladribine tablets 3.5 mg/kg (n=62), and cladribine tablets 5.25 mg/kg (n=70).

2023-05-16 | GSE185773 | GEO

Whole Blood Cell Gene Expression Profiling in Patients with Coronary Artery Disease (Homo sapiens)

Project description:This SuperSeries is composed of the following subset Series: GSE20680: Whole Blood Cell Gene Expression Profiling in Patients with Coronary Artery Disease from the Cathgen Registry GSE20681: Whole Blood Cell Gene Expression Profiling in Patients with Coronary Artery Disease from the PREDICT Trial Refer to individual Series

2011-03-01 | E-GEOD-20686 | biostudies-arrayexpress

Homo sapiens

Project description:Alanyl-glutamine in peritoneal dialysis fluids - a randomized controlled phase I/II trial

| PRJNA245367 | ENA

Differential gene expression in circulating leukocytes from breast cancer patients treated with Cognitive Behavioral Stress Management

Project description:Gene expression profiling was carried out on peripheral blood mononuclear cell mRNA samples collected from 53 female breast cancer patients at 6- or 12-month follow-ups in a randomized controlled trial of Cognitive Behavioral Stress Management or an active control condition. The primary research question is whether gene expression differs in patients treated with Cogntive Behavioral Stress Management vs control conditions. Gene expression profiling was carried out on peripheral blood mononuclear cell mRNA samples collected from 53 female breast cancer patients at 6- or 12-month follow-ups in a randomized controlled trial of Cognitive Behavioral Stress Management or an active control condition. The primary research question is whether gene expression differs in patients treated with Cogntive Behavioral Stress Management vs control conditions. Risk prediction

2012-01-01 | E-GEOD-24079 | biostudies-arrayexpress

Gene eRandomized Controlled Trial of the Gastrin Receptor Antagonist Netazepide in Patients with Barrett’s Esophagus

Project description:A randomized, double-blind, placebo-controlled trial of netazepide (YF476) in patients with BE without dysplasia was performed. Gene expression before and after treatment with netazepide and with a placebo was measured with RNASeq

2021-12-22 | GSE155665 | GEO

Homo sapiens

Project description:Steroid Pretreatment of Organ Donors to Prevent Postischemic Renal Allograft Failure: A Randomized, Controlled Trial

| PRJNA112335 | ENA